Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab open-label study in refractory urticarial vasculitis
2010-020063-21Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in urticarial vasculitis (UV), sponsored by Charité – Universitätsmedizin Berlin. Started May 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
urticarial vasculitis (UV)
Beyond the preview
Go deeper on 2010-020063-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020063-21.